Shanghai MicroPort Endovascular MedTech Co., Ltd. (688016.SS)
CNY 113.48
(-0.65%)
CNY 113.48
(-0.65%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 624.29 Million CNY | 27.36% |
| 2022 | 469.52 Million CNY | 16.1% |
| 2021 | 390.16 Million CNY | 46.82% |
| 2020 | 265.27 Million CNY | 55.16% |
| 2019 | 175.1 Million CNY | 50.1% |
| 2018 | 108.92 Million CNY | 40.77% |
| 2017 | 75.52 Million CNY | 57.97% |
| 2016 | 47.37 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 250.9 Million CNY | 23.38% |
| 2024 Q1 | 221.27 Million CNY | 63.55% |
| 2024 Q3 | 221.48 Million CNY | -38.28% |
| 2023 Q4 | 120.44 Million CNY | -5.22% |
| 2023 Q3 | 127.06 Million CNY | -31.98% |
| 2023 Q2 | 186.81 Million CNY | 27.85% |
| 2023 FY | - CNY | 27.36% |
| 2023 Q1 | 146.12 Million CNY | 111.46% |
| 2022 Q2 | 109.13 Million CNY | -23.52% |
| 2022 Q1 | 142.69 Million CNY | 95.7% |
| 2022 Q3 | 99.91 Million CNY | -8.45% |
| 2022 FY | - CNY | 16.1% |
| 2022 Q4 | 69.1 Million CNY | -30.84% |
| 2021 Q3 | 76.57 Million CNY | -25.25% |
| 2021 Q4 | 72.91 Million CNY | -4.78% |
| 2021 FY | - CNY | 46.82% |
| 2021 Q2 | 102.43 Million CNY | -11.24% |
| 2021 Q1 | 115.4 Million CNY | 52.06% |
| 2020 Q2 | 64.95 Million CNY | 0.91% |
| 2020 Q1 | 64.36 Million CNY | 103.11% |
| 2020 FY | - CNY | 55.16% |
| 2020 Q4 | 75.89 Million CNY | 60.79% |
| 2020 Q3 | 47.2 Million CNY | -27.33% |
| 2019 Q3 | 29.37 Million CNY | 282.66% |
| 2019 Q2 | 7.67 Million CNY | -91.67% |
| 2019 Q1 | 92.11 Million CNY | 437.45% |
| 2019 FY | - CNY | 50.1% |
| 2019 Q4 | 31.69 Million CNY | 7.91% |
| 2018 Q1 | 66.53 Million CNY | 0.0% |
| 2018 FY | - CNY | 40.77% |
| 2018 Q4 | 17.13 Million CNY | -6.27% |
| 2018 Q3 | 18.28 Million CNY | 259.19% |
| 2018 Q2 | 5.09 Million CNY | -92.35% |
| 2017 FY | - CNY | 57.97% |
| 2016 FY | - CNY | 0.0% |